摘要
沙利度胺是一种致畸多种器官的致畸因子,但主要是引起肢体截肢如短肢。在二十世纪五十年代,发现啮齿目动物对沙利度胺具有抗性,这导致了动物试验的失败,以及孕妇使用该药物抗孕吐安全的致命错误。结果导致欧洲有10.000多名婴幼儿出生缺陷这成为史上最大的丑闻之一。尽管如此,沙利度胺仍然具有现代医学的地位,因为其抗炎,免疫调节和抗血管生成活性具有很强的治疗潜力,它已被FDA批准用于多发性骨髓瘤和红斑结节性红斑难治性疾病。目的是为了开发保持治疗潜力并且不致畸的衍生物,这需要关于基础分子机制的详细知识。在过去十年的破译致畸机制方面取得了很大进展。在这里,我们总结这些机制,解释啮齿动物的沙利度胺抗性,并讨论可能的机制,解释为什么药物主要针对胚胎发育中的肢体。最后,我们讨论哪些治疗和致畸机制不重叠,如果有机会可发展具有治疗潜力的非致畸性沙利度胺衍生物。
关键词: 致畸原,肢体截短,氧化应激,血管发生,CRBN,TNFα,炎症,抗癌药物。
Current Molecular Medicine
Title:The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Volume: 17 Issue: 2
关键词: 致畸原,肢体截短,氧化应激,血管发生,CRBN,TNFα,炎症,抗癌药物。
摘要: Thalidomide is a teratogen that affects many organs but primarily induces limb truncations like phocomelia. Rodents are thalidomide resistant. In the 1950s, this has led to misinterpretations of animal tests and to the fatal assumption that the drug was safe for pregnant women to use against morning sickness. The result was one of the biggest scandals in medical history: 10.000 and more infants with birth defects in Europe. Nonetheless, thalidomide still has its place in modern medicine as it has strong therapeutic potential: it has been approved by the FDA for multiple myeloma and erythema nodosum leprosum, and its anti-inflammatory, immunomodulatory and antiangiogenic activities are considered in many other refractory diseases. The aim is to develop derivatives that are not teratogenic but maintain the therapeutic potential. This requires detailed knowledge about the underlying molecular mechanisms. Much progress has been made in deciphering the teratogenic mechanisms in the last decade. Here, we summarize these mechanisms, explain thalidomide resistance of rodents, and discuss possible mechanisms that could explain why the drug primarily targets the developing limb in the embryo. We also summarize the most important therapeutic mechanisms. Finally, we discuss which therapeutic and teratogenic mechanisms do and do not overlap, and if there is a chance for the development of non-teratogenic thalidomide derivatives with therapeutic potential.
Export Options
About this article
Cite this article as:
The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine, Current Molecular Medicine 2017; 17 (2) . https://dx.doi.org/10.2174/1566524017666170331162315
DOI https://dx.doi.org/10.2174/1566524017666170331162315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Colorectal, Prostate and Pancreas Human Cancers Targeted Bioassay-guided Isolations and Characterization of Chemical Constituents from Tephrosia apollinea
Anti-Cancer Agents in Medicinal Chemistry Two Handy Geometric Prediction Methods of Cancer Growth
Current Medical Imaging The Importance of Integrating SNP and Cheminformatics Resources to Pharmacogenomics
Current Drug Metabolism Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry Characterization of Dopamine Receptor Associated Drugs on the Proliferation and Apoptosis of Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Genomics-Based Identification of Molecular Mechanisms behind the Cancer Preventive Action of Phytochemicals: Potential and Challenges
Current Pharmaceutical Biotechnology Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Recent Patents on Anti-Cancer Drug Discovery Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies GnRH-Analogues for Ovarian Protection in Childhood Cancer Patients: How Adult Hypotheses are Relevant in Prepubertal Females
Current Drug Targets Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
Current Pharmaceutical Design Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design MiR-493 Induces Cytotoxic Autophagy in Prostate Cancer Cells through Regulation on PHLPP2
Current Pharmaceutical Biotechnology P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses
Current Medicinal Chemistry Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry